Skip to content
Screener

Erasca, Inc. ERAS Debt-to-equity

Debt-to-equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.9×-0.9×
Eli Lilly logo
Eli LillyLLY
1.6×-0.6×
Pfizer logo
PfizerPFE
0.7×0.0×
Amgen logo
AmgenAMGN
4.9×-2.7×
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
0.1×0.0×
Tango Therapeutics logo
Tango TherapeuticsTNGX
0.1×-0.1×

Other financials

Income statement

See full
Operating income-$187.9M-427%
Net income-$183.4M-492%
EPS (diluted)-$0.60-445%

Balance sheet

See full
Cash & equivalents$47.3M-33.0%
Total debt$46.0M-9.6%
Total equity$393.5M-1.5%
Total assets$461.2M-2.1%

Cash flow

See full
Operating cash flow-$27.4M+13.2%
CapEx$36.0K-56.6%
Free cash flow-$27.4M+13.3%

Valuation

See full
Market cap$6.34B+1,466%
Enterprise value$6.34B+1,533%

Returns & leverage

See full
Return on equity-69.9%+77.1pp
Current ratio9.5×-2.8×

Where this comes from

Calculated from Erasca, Inc.’s reported figures.

Based on the most recent quarter.

The source filing: Erasca, Inc.’s 10-Q, filed May 11, 2026. Open the filing →

Filed
May 11, 2026, 4:13 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-216788

FAQ

What is Erasca, Inc.'s debt-to-equity?
Erasca, Inc. (ERAS) reported debt-to-equity of 0.1× in Q1 2026.
How has Erasca, Inc.'s debt-to-equity changed year-over-year?
Erasca, Inc.'s debt-to-equity decreased by 8.2% year-over-year, from 0.1× to 0.1×.
What is the long-term trend for Erasca, Inc.'s debt-to-equity?
Over 4 years (2021 to 2025), Erasca, Inc.'s debt-to-equity has grown at a 37.0% compound annual growth rate (CAGR), from 0× to 0.1×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.

Ask your AI about Erasca, Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude